Bicalutamide | Bicalutamide Canon tablets coated. 150 mg 30 pcs.

Latin name:

Bicalutamide

Expiration Date: 05/2025

Release form

Film-coated tablets.

Packing

30 pcs

Indications

Prostate cancer - as part of combination therapy with an analog of GnRH or with surgical castration.

Contraindications

Concomitant use with terfenadine, astemizole, cisapride

children

hypersensitivity to bicalutamide

is not prescribed to female patients.

Use during pregnancy and lactation

Do not use in female patients.

Composition

1 tablet contains:

Active substances:

bicalutamide 150 mg.

Excipients:

corn starch 107 mg,

croscarmellose sodium 19.5 mg,

lactose monohydrate 132.9 mg,

povidone 7.6 mg,

sodium stearyl fumarate 3 mg.

Composition of the film coat:

Opadry II white 12 mg.

Dosage and administration

Individual, depending on the indications and treatment regimen.

Side effects of

From the endocrine system: hot flashes, tenderness of the mammary glands and gynecomastia, decreased libido.

From the digestive system: abdominal pain, diarrhea, nausea, vomiting, increased levels of transaminases, jaundice, cholestasis.

From the side of the central nervous system: asthenia, depression are possible.

Dermatological reactions: alopecia, hair growth restoration, itching, dry skin.

Other: hematuria.

Drug Interaction

When using bicalutamide for 28 days on midazolam administration, midazolam AUC increased by 80%.

When bicalutamide is co-administered with cyclosporine or calcium channel blockers, potentiation or development of adverse reactions is possible.

It is theoretically possible to increase the concentration of bicalutamide in blood plasma when co-administered with inhibitors of microsomal liver enzymes, which may be accompanied by an increase in the incidence of adverse reactions.

In vitro studies have shown that bicalutamide can displace the anticoagulant coumarin series warfarin from plasma protein binding sites.

Overdose

There have been no cases of overdose in humans. There is no specific antidote.

Treatment is symptomatic. Dialysis is not effective, as bicalutamide binds strongly to proteins and is not excreted by the kidneys unchanged.

General supportive therapy and monitoring of vital functions of an organism are shown.

Storage conditions

Store in a dry, dark place at a temperature not exceeding 25 РC.

Keep out of the reach of children.

Expiration

2 years.

Deystvuyuschee substances

Bykalutamyd

dosage form well

Dosage Formsand

tablets